Bumetanide |
Infants, children, young adults |
9 |
No detected difference in CR with age |
Marshall et al. [9] |
Cyclosporin |
3 months to 39 years |
56 |
Increased CR effect in <1 to 4 age group |
Marshall et al. [10] |
Lansoprazole |
18 days to 14 years |
40 |
Increased antisecretory effect in infants <6 months |
Tran et al. [11] |
Midazolam |
Pre term 29 weeks |
31 |
Decreased CR (sedation response) |
de Wildt et al. [12] |
Mivacurium |
3–6 years, 10–14 years |
10, 10 |
No major differences in PK-PD |
Stergaard et al. [13] |
Nizatidine |
5 days to 50 years |
93 |
Possible greater CR effect in children? |
Abdel-Rahman et al. [14] |
Ranitidine |
4–11 years |
29 |
No major differences in PK-PD |
Orenstein et al. [15] |
Rocuronium |
Infants, children, adult |
14, 23, 21 |
Greater CR effect in infants compared with children |
Saldien et al. [16] |
Sotolol for SVT |
0.03–41 years |
81 |
Increased CR (QTc interval prolongation) in neonates |
Laer et al. [17] |
Warfarin |
1–11 years, 12–18 years, 37–76 years |
38, 15, 81 |
Increased CR effect (INR/dose) in 1–11 age group |
Takahashi et al.[18] |